Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) is expected to release its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Legend Biotech to post earnings of ($0.34) per share and revenue of $190.83 million for the quarter.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings data on Tuesday, March 11th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.46. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The company had revenue of $186.50 million during the quarter, compared to analyst estimates of $179.00 million. During the same quarter last year, the firm posted ($0.40) EPS. The business’s revenue for the quarter was up 134.6% on a year-over-year basis. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Performance

NASDAQ:LEGN opened at $31.58 on Monday. Legend Biotech has a twelve month low of $29.27 and a twelve month high of $60.87. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average of $34.05 and a 200-day moving average of $36.27. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of -33.24 and a beta of 0.20.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LEGN. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Legend Biotech in a research report on Wednesday, April 16th. Morgan Stanley reduced their price objective on shares of Legend Biotech from $82.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Royal Bank of Canada restated an “outperform” rating and set a $84.00 price objective on shares of Legend Biotech in a research report on Tuesday, April 22nd. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Legend Biotech in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.82.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).